FDA Proposal Set to Cut Biocon's Biosimilar Development Costs by Half: Impact on Global Healthcare Access

Nov 14, 2025 03:04 am CST

India's Biocon anticipates a 50% reduction in biosimilar development costs following the FDA's proposal to simplify clinical testing requirements. The company, which reported 25% growth in biosimilar revenue and holds significant U.S. market share for oncology medications, plans to launch 20 biosimilars by 2030 while expanding into the weight-loss drug market.